The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients
Table 3
Cost-effectiveness analysis of the study.
Parameters
EpoB
CERA
75
75
Patients successfully treated (%) Hb 10.5–12 g/dL
49 (65.3)
53 (70.7)
0.008
Patients not successfully treated (%) Hb > 12 or Hb < 10.5 g/dL
26 (34.7)
22 (29.3)
0.001
Drug costs $
Mean 6-month drug cost per patient
1644.2 ± 859.4
1515.5 ± 713
0.03
Mean 1-year drug cost per patient
3288.49
3030.19
0.03
Incremental 1-year cost Cera versus EpoB $
—
−258.3
Average effectiveness
0.55
0.59
Incremental effectiveness Cera versus EpoB $
—
+0.04
Average cost-effectiveness ratio $/per one per cent of patients successfully treated
6013.86
5173.64
ICER Cera versus EpoB $/per one per cent of patients successfully treated
